Abano Healthcare Group is a New Zealand owned company, operating in the healthcare sector in Australia and New Zealand, and listed on the NZX.
Abano operates successful businesses in two sectors of the healthcare market. We co-invest with clinical leaders and founders in businesses which have growth and profit enhancement opportunities.
Abano is a leading healthcare investor and operator, and listed on the New Zealand Stock Exchange.
Our success is derived from our people, whose commitment, expertise and enthusiasm lead to an improvement in the health and quality of life for the thousands of people we diagnose, care for and treat every day of the year.
On 26 July 2017, Abano Healthcare Group LImited announced a fully underwritten 1 for 5 pro-rata renounceable rights offer and a shortfall bookbuild to raise approximately $35 million.
The net proceeds of the offer will be used to provide additional headroom and flexibility for Abano to respond to the increased acquisition opportunity and step up its growth plans in the trans-Tasman dental market, particularly in Australia.
Under the offer, eligible shareholders are entitled (but not obliged) to subscribe for 1 new share for every 5 existing shares held as at 5.00pm on the record date of 3 August 2017, at an issue price of $8.15 per new share. This represents a 13.3% discount to thedividend adjusted closing price of $9.40 per share, based on the 25 July 2017 closing price.
Rights Offer Document
Letter to Shareholders
FY17 Results and Capital Raising Presentation
Capital Raising Announcement: 26 July 2017
Distribution of Offer Document: 4 August 2017
Reminder Letter to Shareholders re Rights Offer: 16 August 2017
Abano Closes Rights Offer and Commences Shortfall Bookbuild: 25 August 2017
Abano Announces Completion of Shortfall Bookbuild: 28 August 2017